December 2nd 2021

CARE paper published in Science Translational Medicine: New cell-free assay

CARE paper published in Science Translational Medicine: New cell-free assay 

A CARE research team developed a cell-free assay to quantify neutralizing antibody responses. Neutralizing antibody responses to SARS-CoV-2 are usually assessed using cell-based assays requiring live virus. These assays are time-consuming and necessitate additional biosafety precautions, thus limiting their clinical use. The new cell-free assay can evaluate effective neutralizing antibody responses to SARS-CoV-2 spike protein variants of concern after natural infection and it can be applied to characterize vaccine-induced antibody responses or to assess the potency of monoclonal antibodies.

To learn more, read the paper in Science Translational Medicine: A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma